Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557237 | 0.94 | SLC16A3 (0.59) | SLC16A3MEN1GAAKMT2APTGER4 | |
| SCHEMBL3559926 | 0.92 | SLC16A3 (0.67) | SLC16A3MEN1GAAKMT2APTGER4 | |
| SCHEMBL3554617 | 0.90 | SLC16A3 (0.68) | SLC16A3MEN1GAAKMT2AHDAC3 | |
| SCHEMBL3560831 | 0.89 | SLC16A3 (0.72) | SLC16A3MEN1GAAKMT2AACLY | |
| SCHEMBL3557971 | 0.85 | MEN1 (0.60) | SLC16A3MEN1GAAKMT2AACLY | |
| SCHEMBL3562298 | 0.85 | MEN1 (0.62) | SLC16A3MEN1GAAKMT2AACLY | |
| SCHEMBL3553847 | 0.85 | SLC16A3 (0.76) | SLC16A3HDAC3NCOR2HDAC1HDAC2 | |
| SCHEMBL3556578 | 0.84 | PSEN1 (0.52) | MEN1GAAKMT2AHDAC3HDAC1 | |
| SCHEMBL3563699 | 0.84 | SLC16A3 (0.60) | SLC16A3MEN1GAAKMT2AHDAC3 | |
| SCHEMBL3559492 | 0.83 | SLC16A3 (0.64) | SLC16A3MEN1GAAKMT2AACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885MEN1 2548/4885GAA 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.